GlaxoSmithKline Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GlaxoSmithKline stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View analyst ratings for GlaxoSmithKline or view top-rated stocks.

Wall Street analysts have given GlaxoSmithKline a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but GlaxoSmithKline wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

GlaxoSmithKline is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for GlaxoSmithKline.

GlaxoSmithKline plc (NYSE:GSK) issued its quarterly earnings data on Wednesday, July, 28th. The pharmaceutical company reported $0.79 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.54 by $0.25. The pharmaceutical company had revenue of $11.31 billion for the quarter, compared to analyst estimates of $10.55 billion. GlaxoSmithKline had a trailing twelve-month return on equity of 26.21% and a net margin of 13.40%.
View GlaxoSmithKline's earnings history.

GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GSK shares have decreased by 2.4% and is now trading at $38.93.
View which stocks have been most impacted by COVID-19.

GlaxoSmithKline announced a quarterly dividend on Friday, July 30th. Shareholders of record on Friday, August 20th will be paid a dividend of $0.523 per share on Thursday, October 7th. This represents a $2.09 dividend on an annualized basis and a dividend yield of 5.37%. The ex-dividend date of this dividend is Thursday, August 19th.
View GlaxoSmithKline's dividend history.

GlaxoSmithKline pays an annual dividend of $2.09 per share and currently has a dividend yield of 5.34%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. GlaxoSmithKline does not yet have a strong track record of dividend growth. The dividend payout ratio of GlaxoSmithKline is 70.13%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GlaxoSmithKline will have a dividend payout ratio of 68.08% next year. This indicates that GlaxoSmithKline will be able to sustain or increase its dividend.
View GlaxoSmithKline's dividend history.

Some companies that are related to GlaxoSmithKline include Roche (RHHBY), Pfizer (PFE), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly and (LLY), AbbVie (ABBV), Novartis (NVS), Merck & Co., Inc. (MRK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Sanofi (SNY), CSL (CSLLY), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN) and Takeda Pharmaceutical (TAK).
View all of GSK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), The Walt Disney (DIS) and NVIDIA (NVDA).

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

GlaxoSmithKline's stock is owned by a number of institutional and retail investors. Top institutional investors include Dodge & Cox (3.28%), Capital International Investors (0.84%), Fisher Asset Management LLC (0.65%), FMR LLC (0.63%), Price T Rowe Associates Inc. MD (0.54%) and Hotchkis & Wiley Capital Management LLC (0.35%).
View institutional ownership trends for GlaxoSmithKline.

GSK stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Credit Suisse AG, Price T Rowe Associates Inc. MD, Hotchkis & Wiley Capital Management LLC, Northern Trust Corp, Susquehanna International Group LLP, State Street Corp, and Haverford Trust Co..
View insider buying and selling activity for GlaxoSmithKline or view top insider-selling stocks.

GSK stock was bought by a variety of institutional investors in the last quarter, including JTC Employer Solutions Trusteee Ltd, BNP Paribas Arbitrage SA, Capital International Investors, Goldman Sachs Group Inc., Fisher Asset Management LLC, Millennium Management LLC, SG Americas Securities LLC, and Black Creek Investment Management Inc..
View insider buying and selling activity for GlaxoSmithKline or or view top insider-buying stocks.

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GSK stock can currently be purchased for approximately $38.93.

GlaxoSmithKline has a market capitalization of $104.82 billion and generates $43.79 billion in revenue each year. The pharmaceutical company earns $7.38 billion in net income (profit) each year or $2.98 on an earnings per share basis.

GlaxoSmithKline employs 94,066 workers across the globe.

GlaxoSmithKline was founded in 2000.

The official website for GlaxoSmithKline is www.gsk.com.

GlaxoSmithKline is headquartered at 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS.

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The pharmaceutical company can be reached via phone at 442080475000 or via email at [email protected]